Elanco Animal Health (NYSE:ELAN) Stock Rating Upgraded by Wall Street Zen

Elanco Animal Health (NYSE:ELAN) was upgraded by investment analysts at Wall Street Zen from a “buy” rating to a “strong-buy” rating in a note issued to investors on Saturday.

ELAN has been the topic of a number of other reports. Stifel Nicolaus raised their price target on Elanco Animal Health from $18.00 to $23.00 and gave the company a “buy” rating in a report on Wednesday, September 24th. Weiss Ratings reissued a “sell (d+)” rating on shares of Elanco Animal Health in a research note on Monday, December 29th. Zacks Research downgraded shares of Elanco Animal Health from a “strong-buy” rating to a “hold” rating in a research report on Thursday, November 6th. UBS Group upped their price target on shares of Elanco Animal Health from $25.00 to $27.00 and gave the stock a “buy” rating in a research note on Thursday, November 6th. Finally, Morgan Stanley raised their price objective on shares of Elanco Animal Health from $18.00 to $22.00 and gave the company an “equal weight” rating in a research note on Thursday, December 18th. Two research analysts have rated the stock with a Strong Buy rating, seven have issued a Buy rating, three have assigned a Hold rating and one has issued a Sell rating to the company. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $23.78.

Elanco Animal Health Price Performance

Shares of NYSE:ELAN opened at $22.53 on Friday. The firm’s 50 day moving average is $22.18 and its two-hundred day moving average is $19.01. The firm has a market capitalization of $11.19 billion, a P/E ratio of 375.51, a PEG ratio of 3.13 and a beta of 1.87. The company has a current ratio of 2.40, a quick ratio of 1.23 and a debt-to-equity ratio of 0.59. Elanco Animal Health has a 52 week low of $8.02 and a 52 week high of $23.70.

Elanco Animal Health (NYSE:ELAN) last issued its quarterly earnings data on Wednesday, November 5th. The company reported $0.19 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.13 by $0.06. Elanco Animal Health had a return on equity of 7.41% and a net margin of 0.78%.The business had revenue of $1.14 billion during the quarter, compared to the consensus estimate of $1.09 billion. During the same period in the previous year, the firm posted $0.13 earnings per share. The business’s revenue was up 10.4% on a year-over-year basis. Elanco Animal Health has set its FY 2025 guidance at 0.910-0.940 EPS and its Q4 2025 guidance at 0.090-0.120 EPS. Analysts anticipate that Elanco Animal Health will post 0.91 earnings per share for the current year.

Insider Buying and Selling at Elanco Animal Health

In related news, CFO Robert M. Vanhimbergen acquired 6,950 shares of the business’s stock in a transaction dated Thursday, December 11th. The stock was bought at an average price of $21.64 per share, for a total transaction of $150,398.00. Following the transaction, the chief financial officer owned 124,233 shares of the company’s stock, valued at approximately $2,688,402.12. The trade was a 5.93% increase in their ownership of the stock. The purchase was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, Director Lawrence Erik Kurzius bought 10,000 shares of the firm’s stock in a transaction that occurred on Friday, December 12th. The stock was bought at an average price of $21.30 per share, for a total transaction of $213,000.00. Following the completion of the acquisition, the director directly owned 131,773 shares in the company, valued at approximately $2,806,764.90. The trade was a 8.21% increase in their ownership of the stock. The SEC filing for this purchase provides additional information. Insiders acquired 43,450 shares of company stock valued at $937,883 in the last ninety days. Company insiders own 0.89% of the company’s stock.

Institutional Investors Weigh In On Elanco Animal Health

Several hedge funds have recently modified their holdings of ELAN. HighTower Advisors LLC lifted its holdings in shares of Elanco Animal Health by 7.0% during the 1st quarter. HighTower Advisors LLC now owns 12,445 shares of the company’s stock valued at $131,000 after buying an additional 810 shares during the last quarter. Comerica Bank raised its holdings in Elanco Animal Health by 46.4% in the 1st quarter. Comerica Bank now owns 49,680 shares of the company’s stock worth $522,000 after acquiring an additional 15,754 shares during the period. Vident Advisory LLC lifted its position in Elanco Animal Health by 46.5% during the 1st quarter. Vident Advisory LLC now owns 14,808 shares of the company’s stock worth $155,000 after acquiring an additional 4,698 shares during the last quarter. AQR Capital Management LLC boosted its holdings in Elanco Animal Health by 116.4% during the first quarter. AQR Capital Management LLC now owns 524,507 shares of the company’s stock valued at $5,332,000 after acquiring an additional 282,081 shares during the period. Finally, MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. acquired a new stake in Elanco Animal Health in the 1st quarter valued at approximately $2,065,000. 97.48% of the stock is owned by hedge funds and other institutional investors.

Elanco Animal Health Company Profile

Elanco Animal Health Inc is a global leader in animal health dedicated to improving food and companion animal well-being. The company develops, manufactures and markets a range of products, including parasiticides, vaccines, antibiotics and feed additives designed to prevent and treat disease in livestock and pets. Elanco’s portfolio spans both food-producing animals—such as cattle, swine, poultry and aquaculture—and companion animals, with offerings that support parasite control, pain management and infectious disease prevention.

Originally founded as the animal health division of Eli Lilly and Company in the mid-20th century, Elanco was spun off into an independent publicly traded company in 2018.